Global Ertapenem Injection Market Size, Share and Trends Analysis Report, By Type (INVANZ and Generic Version), and By Application (Children and Adults), Forecast (2022-2028)

The global ertapenem injection market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Ertapenem injection is prescribed primarily to treat high-risk and serious bacterial infections including urinary tract, skin, diabetic, foot, gynaecological, pelvic, and abdominal infection. It is also used after surgery to prevent infections. The ertapenem injection market is witnessing significant growth during the forecast period, due to the increasing prevalence of infection across the globe. According to the Centres for Disease Control and Prevention 2019, around 2.8 million populations get affected by bacterial infection and 35,000 deaths every year are caused by antibiotic-resistant bacteria and fungi in the US.

Additionally, the rising need and demand for minimally invasive surgeries globally is another factor which is expected to bolster the growth of the ertapenem injection market. as this injection is also prescribed after several surgeries to prevent infections. According to the article by the US National Library of Medicine in December 2021, an estimation of 13,108,567 surgical procedures was identified from January 1, 2019, to January 30, 2021, in the US.

For instance, in May 2021, Dr. Reddy’s Laboratories Ltd. announced their US Food and Drug Administration approval for the launch of Ertapenem for Injection in 1 g/vial which is a generic version of INVANZ. In June 2018, Aurobindo Pharma announced their USFDA approval for manufacturing Ertapenem Injection 1 g/vial. In July 2018, Endo Pharmaceuticals Inc. announced that their operating company, Par Pharmaceutical, has begun shipping an authorized generic version of INVANZ ertapenem injection. Endo’s subsidiary and Endo Ventures Limited has made an exclusive U.S. supply and distribution agreement with Merck & Co., Inc., allowing Par Pharmaceutical to launch and distribute the authorized generic of the ertapenem injection.

Some major players in the market include Merck & Co., Inc., Endo International plc, Aurobindo Pharma, and ACS Dobfar S.p.A. among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new drug launches, to stay competitive in the market. For instance, in June 2021, JW Pharmaceutical announced their entry into the ertapenem injection market by using active pharmaceutical ingredients made with their technology by JW Pharmaceutical in Korea. It has been approved by USFDA and the product has been launched in the US market.

Market Coverage

• The market number available for – 2022-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Merck & Co., Inc., Endo International plc, Aurobindo Pharma, and ACS Dobfar S.p.A. among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Ertapenem Injection Market Report by Segment

By Type

• INVANZ
• Generic Version

By Indication

• Children
• Adults

Global Ertapenem Injection Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa